HCPCS Level II code J2650 denotes an injection of prednisolone acetate, up to 1 ml, a commonly used ophthalmic corticosteroid for intraocular or periocular anti-inflammatory therapy. This code matters nationally because it captures billing for a routine therapeutic procedure in eye care, with implications for outpatient reimbursement, utilization monitoring, and formulary management. Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn what the code represents clinically and operationally, how major payers typically approach coverage and billing for injectable ophthalmic corticosteroids, and what benchmarks and policy considerations are relevant for outpatient ophthalmology services. The publication provides context on service settings where J2650 is used, common billing practices for single-dose ocular injections, and areas where policy updates or payer guidance can affect claims handling. Data not available in the input for specific payer policies, fee schedules, or ICD-10 linkage is noted where applicable. The focus is national in scope and oriented toward helping billing managers, revenue cycle professionals, and clinical administrators understand the role and billing context of HCPCS Level II code J2650 within outpatient ophthalmic care.